Oncimmune Holdings PLC (AIM:ONC) said it has signed a collaboration to profile samples from Genentech's rheumatology clinical trials, broadening the "commercial footprint” of its ImmunoINSIGHTS service business.
Oncimmune’s NavigAID arrays will be used to characterise the auto-antibody profiles of patients taking part in studies for rheumatological diseases, including the autoimmune disease lupus.
Following the project’s completion, Genentech, which is now part of Swiss giant Roche, has the option to expand the contract to profile additional samples.
"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” Oncimmune chief executive, Dr Adam Hil said in a statement.
“This contract adds to the already substantial pipeline of contracted revenue through our ImmunoINSIGHTS business in the full-year 2021 and provides another opportunity to show how our NavigAID technology can assist partners in increasing their ability to better assess where their medicines could make an impact,” he added.